USANA Health Sciences's Earnings Beat Last Year's by 42%

USANA Health Sciences (NYSE: USNA  ) reported earnings on April 23. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 30 (Q1), USANA Health Sciences met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded. GAAP earnings per share increased significantly.

Gross margins contracted, operating margins grew, net margins grew.

Revenue details
USANA Health Sciences notched revenue of $169.1 million. The four analysts polled by S&P Capital IQ wanted to see sales of $170.4 million on the same basis. GAAP reported sales were 9.7% higher than the prior-year quarter's $154.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.28. The five earnings estimates compiled by S&P Capital IQ averaged $1.16 per share. GAAP EPS of $1.28 for Q1 were 42% higher than the prior-year quarter's $0.90 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 82.1%, 20 basis points worse than the prior-year quarter. Operating margin was 15.7%, 220 basis points better than the prior-year quarter. Net margin was 10.5%, 160 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $176.1 million. On the bottom line, the average EPS estimate is $1.30.

Next year's average estimate for revenue is $712.2 million. The average EPS estimate is $5.18.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 225 members out of 407 rating the stock outperform, and 182 members rating it underperform. Among 119 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give USANA Health Sciences a green thumbs-up, and 66 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on USANA Health Sciences is outperform, with an average price target of $57.00.

Looking for alternatives to USANA Health Sciences? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.

Add USANA Health Sciences to My Watchlist.